Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | HBB | P68871 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL825780 | 0.97 | APP (0.55) | APPLMNATSHRALDH1A1PMP22 | |
| SCHEMBL11883063 | 0.87 | DNM1 (0.50) | APPLMNATSHRALDH1A1PMP22 | |
| SCHEMBL17495626 | 0.87 | DNM1 (0.50) | APPLMNATSHRALDH1A1PMP22 | |
| SCHEMBL8413661 | 0.86 | APP (0.52) | APPLMNATSHRALDH1A1PMP22 | |
| SCHEMBL6941022 | 0.86 | APP (0.46) | APPLMNATSHRALDH1A1PMP22 | |
| SCHEMBL9339421 | 0.86 | APP (0.46) | APPLMNATSHRALDH1A1PMP22 | |
| SCHEMBL6044734 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL9326378 | 0.84 | APP (0.50) | APPLMNATSHRALDH1A1PMP22 | |
| Hydrochloric Acid SCHEMBL9175237 | 0.84 | APP (0.44) | APPLMNATSHRALDH1A1PMP22 | |
| Hydrochloric Acid SCHEMBL5618083 | 0.82 | APP (0.48) | APPLMNATSHRALDH1A1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113330020-B | 2-fluoro bile acids for the treatment of neurodegenerative diseases | NZP英国有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-103319382-B | The preparation method of 2-(amino) ethyl-methyl sulfone salt and intermediate thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-03-16 | — | — | CN | claimed |
| CN-101987828-B | 2-(N,N-dibenzylamino) methyl sulfone, and salt and application thereof | SHANGHAI KNOWA PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-11-05 | — | — | CN | claimed |
| US-20140294704-A1 | SOLVENT AND METHOD FOR REMOVAL OF AN ACID GAS FROM A FLUID STREAM | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-10-02 | — | — | US | claimed |
| CN-103319382-A | Preparation methods of 2-(amino)ethyl methyl sulfone salt and intermediate of 2-(amino)ethyl methyl sulfone salts | SHANGHAI INST PHARM INDUSTRY | 2013-09-25 | — | — | CN | claimed |
| CN-101987829-A | Novel 2-(amino) ethyl methyl sulfone salt and preparation | SHANGHAI KNOWA PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-23 | — | — | CN | claimed |
| CN-101987828-A | 2-(N,N-dibenzylamino) methyl sulfone, and salt and application thereof | SHANGHAI KNOWA PHARMACEUTICAL TECHNOLOGY CO LTD | 2011-03-23 | — | — | CN | claimed |
| US-20240327411-A1 | SIRT6 ACTIVATORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-03 | — | — | US | disclosed |
| CN-113330020-B | 2-fluoro bile acids for the treatment of neurodegenerative diseases | NZP英国有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3388433-B1 | PHTHALAZINE DERIVATIVES, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMR BIOTECH CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | SHANGHAI SIMR BIOTECH CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| CN-107108634-B | Imidazopyridazine derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | SHANGHAI SIMRD BIOTECHNOLOGY. CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20050009817-A1 | Substituted heteroaryls | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-13 | — | — | US | disclosed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2004099159-A1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004063348-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003101978-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220503-B2 | Phthalazine derivatives, preparation method, pharmaceutical composition and usage thereof | GABRA5, CYP3A5, GABRA1 | APP 915/4885LMNA 3499/4885TSHR 389/4885 |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | APP 4181/4885LMNA 4738/4885TSHR 943/4885 |
| US-20050009817-A1 | Substituted heteroaryls | PTPRS, PTPRO, PTPRR | APP 1297/4885LMNA 4360/4885TSHR 1562/4885 |
| US-20200165253-A1 | Phthalazine Derivatives, Preparation Method, Pharmaceutical Composition and Usage Thereof | GABRA5, CYP3A5, GABRA1 | APP 915/4885LMNA 3499/4885TSHR 389/4885 |
| US-20240327411-A1 | SIRT6 ACTIVATORS | SIRT6, SIRT1, SIRT2 | APP 966/4885LMNA 3730/4885TSHR 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.